JAK inhibitors market size rose 54%↑over the year
By Kim, Jin-Gu | translator Kang, Shin-Kook
24.08.12 06:03:00
가나다라
0
The JAK inhibitors market reached prescription sales of KRW 27.5 billion in the first half of 2024…skyrocketing compared to KRW 17.8 billion in the same period
Rinvoq KRW 11.2B>Olumiant KRW 8B>Xeljanz KRW 6.9B…latecomers begin expanding prescription areas
▲(Clockwise from upper left) product photos of Jyseleca, Cibinqo, Rinvoq, Olumiant, and Xeljanz.
The market for Janus Kinase (JAK) inhibitors, oral medicines used to treat autoimmune diseases, is growing rapidly following the approval of major medicines for expanded indications.In the first half of the year, the market for JAK inhibitors reached KRW 27.5 billion in outpatient sales, up 54% year over year (YoY).
Abbvie's 'Rinvoq (upadacitinib)' occupies the No.1 slot among the major products with a considerable margin over other products. Lily's 'Olumiant (baricitinib),' Pfizer's 'Xeljanz (tofacitinib)'·'Cibinqo (abrocitinib),' and Eisai's 'Jyseleca (filgotinib)' are increasing prescription performance.
The JAK inhibitors market grew 54% over the year…market siz
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)